IOBT Stock Analysis: Buy, Sell, or Hold?
IOBT - IO Biotech, Inc. Common Stock
$0.03
-0.01 (-30.66%)
▼
5d:
-85.22%
30d:
-90.87%
90d:
-95.02%
WAIT
LOW Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: Mar 30, 2026
0d
Get Alerted When IOBT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: IOBT is down 85.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: IOBT is down 85.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: IOBT is currently trading at $0.03, which is considered oversold relative to its 30-day fair value range of $0.14 to $0.32.
Technical Outlook: Technically, IOBT is in a strong downtrend. The price is currently testing key support at $0.03. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 30.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $2.18 (+4888.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IOBT is in a strong downtrend. The price is currently testing key support at $0.03. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 30.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $2.18 (+4888.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$0.14 -
$0.32
Company Quality Score
37/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
72.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BEARISH: Downward momentum (-30.7%)
- BULLISH: Trading 4888.6% below Wall St target ($2.18)
- WARNING: Recommendation downgraded due to -85.2% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$0.14 -
$0.32
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$0.03
Resistance Level
$0.22
Current Trend
Strong Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.12
Wall Street Target
$2.18
(+4888.6%)
Share & Embed Analysis
Last updated: April 02, 2026 12:30 PM ET
Data refreshes hourly during market hours. Next update: 1:30 PM
Data refreshes hourly during market hours. Next update: 1:30 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IOBT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1018 | 55 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 59 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 59 HOLD |
